Leerink Partnrs Issues Negative Estimate for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research report issued on Wednesday, February 19th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.75) for the year, down from their prior forecast of ($0.66). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share.

KPTI has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. Piper Sandler increased their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

KPTI stock opened at $0.57 on Monday. Karyopharm Therapeutics has a 12 month low of $0.51 and a 12 month high of $1.70. The firm has a market capitalization of $72.07 million, a PE ratio of -0.56 and a beta of 0.06. The company’s 50 day simple moving average is $0.66 and its 200-day simple moving average is $0.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in Karyopharm Therapeutics by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after buying an additional 36,922 shares during the period. Silverarc Capital Management LLC increased its stake in shares of Karyopharm Therapeutics by 6.7% during the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock valued at $403,000 after acquiring an additional 37,524 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in shares of Karyopharm Therapeutics during the 4th quarter worth about $27,000. Two Sigma Advisers LP boosted its position in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after acquiring an additional 45,400 shares during the last quarter. Finally, Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics in the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).